Breaking News

Lilly, HAYA to Target Obesity and Metabolic Conditions in Potential $1B Pact

Will apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, entered a multi-year agreement with Eli Lilly and Co. to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The companies aim to identify multiple regulatory genome derived RNA-based drug targets to treat these conditions.   HAYA will receive an upfront payment, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters